复星医药：控股子公司复宏汉霖与Eisai签订许可协议

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Fuhong Hanlin, has signed a licensing agreement with Eisai for the development, production, and commercialization of Surufatinib injection in Japan for oncology indications [1] - The agreement includes an upfront payment of up to $15.51 million, regulatory milestone payments, and sales milestone payments of up to $23.33 million, along with royalties [1] - This collaboration is expected to help Fosun Pharma expand its product presence in overseas markets [1] Group 2 - The article notes that drug development carries inherent uncertainties, and the collection of related payments also involves uncertainties [1]